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Abstract
Background: The majority of schistosomiasis control programmes focus on targeting school-aged children. Expanding
the use of community-wide mass treatment to reach more adults is under consideration. However, it should be noted
that this would require a further increase in programmatic resources, international aid, and commitment for the
provision of praziquantel. Consequently, it is important to understand (i) where a change of strategy would have the
greatest benefit, and (ii) how generalisable the conclusions of field trials and analytical studies based on mathematical
models investigating the impact of community-wide mass treatment, are to a broad range of settings.
Methods: In this paper, we employ a previously described deterministic fully age-structured schistosomiasis
transmission model and evaluate the benefit of community-wide mass treatment both in terms of controlling
morbidity and eliminating transmission for Schistosoma mansoni, across a wide range of epidemiological settings
and programmatic scenarios. This included variation in the baseline relative worm pre-control burden in adults,
the overall level of transmission in defined settings, choice of effectiveness metric (basing morbidity calculations
on prevalence or intensity), the level of school enrolment and treatment compliance.
Results: Community-wide mass treatment was found to be more effective for controlling the transmission of
schistosome parasites than using a school-based programme only targeting school-aged children. However, in
the context of morbidity control, the potential benefit of switching to community-wide mass treatment was highly
variable across the different scenarios analysed. In contrast, for areas where the goal is to eliminate transmission,
the projected benefit of community-wide mass treatment was more consistent.
Conclusion: Whether community-wide mass treatment is appropriate will depend on the local epidemiological setting
(i.e. the relative pre-control burden in adults and transmission intensity), and whether the goal is morbidity control or
eliminating transmission. This has important implications regarding the generalisability of cost-effectiveness analyses of
schistosomiasis interventions. Our results indicate that areas with poor school-enrolment/coverage could benefit more
from community-wide treatment of praziquantel and should potentially be prioritised for any change in strategy. This
work highlights the importance of not over-generalising conclusions and policy in this area, but of basing decisions on
high quality epidemiological data and quantitative analyses of the impact of interventions in a range of settings.
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Background
Schistosomiasis, also known as snail fever or bilharziasis,
is a neglected tropical disease (NTD) caused by parasitic
flatworms belonging to the genus Schistosoma. There
are two major forms of human schistosomiasis, intes-
tinal and urogenital, which are caused by five main spe-
cies of blood fluke. Schistosomiasis affects almost 240
million people worldwide, and more than 700 million
people are at risk of infection [1]. At present, it is pre-
dominantly controlled by school or community-based
mass drug administration (MDA) using praziquantel.
The majority of schistosomiasis control programmes
focus on targeting school-aged children (SAC), via
school-based treatment programmes. In some areas,
adults are also targeted, ranging from high-risk groups
to the entire community [2]. The current World Health
Organization (WHO) goals for schistosomiasis are out-
lined in Table 1.
The global treatment coverage for schistosomiasis is the
lowest of all the helminth diseases treated with preventive
chemotherapy. Although it has improved recently, schisto-
somiasis remains classed as red by the annual score card
developed by Uniting to Combat NTDs [3]. In 2014 the
coverage of at risk SAC and adults was estimated to be 24
and 9%, respectively [4]. This is in spite of a recent in-
crease in the availability of donated praziquantel (Merck
KGaA has now increased its donation of praziquantel to
up to 250 million tablets a year, equivalent to 100 million
treatments [5]).
There is a growing body of evidence regarding the
burden of infection and morbidity in adults, as well as
the potential role of these age groups in sustaining trans-
mission [4, 6–11]. This points to a greater need for inclu-
sion of adults in schistosomiasis preventive chemotherapy
treatment programmes in some endemic settings. While
expanding the use of community-wide mass treatment to
reach more adults is under consideration [12, 13] this
would require a further increase in programmatic re-
sources and international commitment. The main bottle-
neck to schistosomiasis control efforts at present is not
the availability of donated praziquantel, but resources and
funds for its delivery (especially in remote and hard to
reach settings) [14].
Although several field studies have been conducted to
investigate the benefit of community-wide mass treat-
ment for schistosomiasis control, findings have been in-
consistent [15–18] and some studies find no significant
difference when comparing its impact to school-based
treatment. Furthermore, Butterworth and colleagues [19]
performed studies in Kenya, comparing the long-term
impact of different methods of administration of chemo-
therapy (selective treatment to all infected individuals,
selective treatment to individuals with heavy infections,
and selective treatment of infected school children). The
arm performing selective treatment of all infected indi-
viduals showed the greatest relative reductions in infec-
tion prevalence and intensity (however, some earlier
interventions had been carried out in this area and the
pre-treatment intensities were lower than the other
arms). The arm providing treatment only to infected
schoolchildren also had a marked and prolonged effect
(which was comparable to - if not better than - selective
treatment of individuals with heavy infections). It was con-
cluded that, in areas of low morbidity, chemotherapy of
SAC alone is a satisfactory way of producing a long-term
reduction in both infection intensity and morbidity [19].
It is important that we understand the variability of
the impact of using community-wide mass treatment
across different settings, and in what circumstances it
has the greatest benefit (particularly as the relative pre-
control burden in adults, has been observed to vary
across different settings (Fig. 1) [20]). In this study, we
use a mathematical model to evaluate the projected
benefit of using annual community-wide mass treatment
in terms of both controlling morbidity and eliminating
transmission for Schistosoma mansoni (the most preva-
lent of the schistosome species infecting humans). We
investigate how sensitive this projected benefit is to dif-
ferent epidemiological and programmatic assumptions.
We also explore how the benefit of switching to
community-wide mass treatment is influenced by the
chosen effectiveness metric, i.e. what method is used to
approximate MDA’s impact on morbidity. This is important
as there is uncertainty regarding how schistosomiasis
models should approximate the impact of treatment on
morbidity. The principle goal of this research is to gain an
understanding of how generalisable the conclusions of
studies investigating the impact and benefit of community-
wide mass treatment are across different settings.
Table 1 Overview of the WHO 2013 strategic plan for
schistosomiasis [85]
Goals
1. To control morbidity due to schistosomiasis by 2020 (defined as 100%
geographical coverage, 75% national coverage and < 5% prevalence
of heavy-intensity infections across all sentinel sites).
2. To eliminate schistosomiasis as a public-health problem by 2025
(defined as a prevalence of heavy-intensity infections < 1% in all sentinel
sites).
3. To interrupt transmission of schistosomiasis in the Region of the
Americas, the Eastern Mediterranean Region, the European Region,
the South-East Asia Region and the Western Pacific Region, and in
selected countries of the African Region by 2025 (defined as reduction
to zero incidence of infection).
Objectives
1. To scale-up control and elimination activities in all endemic countries
2. To ensure an adequate supply of praziquantel and resources to meet
the demand
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Methods
Mathematical model
In this paper, we employ a previously described deter-
ministic fully age-structured schistosomiasis transmis-
sion and MDA treatment model [4, 21], which assumes
the parasite is dioecious and monogamous, has density-
dependent egg production [22] and a degree of parasite
aggregation defined by the negative binomial probability
distribution with a fixed k value. The model describes
changes in worm burden in order to capture the non-
linear and density dependent processes which influence
the effect treatment has on the rate of transmission,
such as the worm’s mating behaviour and the effect of
infection intensity on the female worm’s fecundity. The
predictions of MDA impact generated by this model are
very similar to a more complex individual-based sto-
chastic model [6]. In the model, we assume that the age-
intensity profiles (Fig. 2) are generated by age-dependent
exposure to the infectious stages in the environment
and not acquired immunity [23]. Although the model
has full age structure, the outputs are grouped into
programmatically meaningful categories such as SAC
(5–14 year- olds) and adults (≥15 year-olds). The response
of the model under treatment has been validated
against data (see [4, 6] for further details). The model has
been adapted to allow for systematic non-compliance
(individuals never taking treatment) [24]. Further detail
regarding the model and its parameters is provided in
Additional file 1.
Model scenarios and sensitivity analysis
We investigated the impact of an annual school-based
treatment programme targeting only SAC, and compared
this with an annual community-wide mass treatment
programme targeting both SAC and adults. Based on a
recent systematic review, we assumed the drug efficacy
of a 40 mg per kg dose of praziquantel was 86.3% for S.
mansoni [25]. In line with WHO guidelines, we assumed
Pre-SAC were not eligible for treatment [26].
We assumed a 75% treatment coverage of the targeted
age groups and a systematic non-compliance rate of 5%,
i.e. 5% of the targeted population never take treatment,
and the rest of the eligible population take it randomly
each round. It should be acknowledged that there are
very little data regarding systematic non-compliance
rates [27] and we, therefore, varied these assumptions in
the sensitivity analysis.
We also considered a scenario where the systematic
non-compliance rate was 20% for the school-based
programme, but 5% when using community-wide mass
treatment, simulating a setting where many of the non-
enrolled SAC are consistently missed by the school-based
Fig. 1 The observed cross-sectional host-age and mean intensity profiles for Schistosoma mansoni and Schistosoma haematobium infection. The data
are from the following sources: Iietune (Kenya) [64], Matithini (Kenya) [64], Katheka village (Kenya) [86], Machakos (Kenya) [87], Misungwi (Tanzania) [88]
Fig. 2 Model scenarios regarding the age-intensity profiles of infection
and the relative pre-control burden in adults. To ensure the results are
comparable, the R0’s were adjusted for these different profile scenarios
such that they had the same pre-control mean worm burden (i.e. we
ensured that we are not comparing the impact of both a different
age-profile and a different initial overall burden). Model parameters
are shown in Additional file 1: Tables S1 and S2
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programme, and only reached through a community-
based programme.
Based on the available age-intensity profiles (Fig. 1)
[6], we defined three scenarios with different levels of
relative pre-control infection burdens in adults (low,
medium and high, see Fig. 2 and Additional file 1: Tables
S1 and S2). These were chosen to represent the observed
variation in the relative burden in adults and were based
on the fits presented in [6]. It should be noted that these
are informed by the limited age-stratified epidemiological
data available on infection intensity, and consequently,
there may be settings that fall outside of this range. The
model was used to simulate two transmission settings: a
higher transmission setting with an overall age-weighted
mean worm burden of 155, based on model fits to the data
[4], and a lower transmission setting with a mean worm
burden of 60. The age-weighted mean egg count per gram
of stool (epg) varied between 158 and 166 for the higher
transmission setting and 76–78 for the lower transmission
setting. The age-weighting accounts for the local demog-
raphy. To ensure the results for the different scenarios are
comparable, the transmission intensity, as represented by
the basic reproduction number (R0), was adjusted such
that the different scenarios were based on pre-control
mean worm burden, i.e. we ensured that we are not com-
paring the impact of both a different age-infection profile
and a different pre-control burden when comparing the
different scenarios. The R0 values ranged between 1.30
and 1.32 for the lower transmission setting and 1.63–1.68
for the higher transmission setting.
The sensitivities of the model projections to the as-
sumed life expectancy of the adult worms (4 years instead
of 5.71), and the treatment coverage and compliance levels
were explored.
Effectiveness metrics
The model was used to investigate three different effect-
iveness metrics (modified from [28]) across the chosen
time horizon (Fig. 3): (i) the total reduction in the overall
worm burden experienced by the population, i.e. number
of years lived with a worm (worm years) averted; (ii) the
total number of prevalent infection case years averted, i.e.
the number of years lived with a prevalent infection pre-
vented; and (iii) the total number of heavy infection case
years averted, i.e. the number of years lived with a heavy
infection prevented. Heavy infection was defined as having
an epg ≥ 400, an established WHO threshold [2].
We also estimated the number of rounds of preventive
chemotherapy required to eliminate transmission - defined
as crossing the breakpoint in transmission where infection
levels settle to the equilibrium of extinction [29].
Results
Impact of school-based treatment
Annual school-based treatment was projected to notably
reduce both the worm burden and prevalence of heavy
infections in SAC. It also has an indirect effect on the
untreated adults due to reductions in transmission
(Figs. 4 and 5). However, the overall impact of school-
based treatment was found to be dependent on the rela-
tive pre-control burden in adults (the shape of the age
intensity of infection profile) and in many settings a sig-
nificant burden would remain even after five years of
treatment (Figs. 4 and 5). The higher the level of transmis-
sion, the greater the significance of this untreated burden
in adults (Figs. 4, 5 and Additional file 1: Figure S1).
Benefit of community-wide mass treatment stratified by
effectiveness metric
A community-wide mass treatment strategy was found
to increase the effectiveness of preventive chemotherapy
against schistosomiasis, though its benefit relative to
school-based treatment was found to vary across the dif-
ferent epidemiological scenarios and the employed effect-
iveness metrics used to quantify the intervention’s impact
on morbidity (Table 2). The main prediction was that
Fig. 3 Schematic representation of the effectiveness metrics. a Reduction in the overall worm burden (worm years averted). b Prevalent infection
case years averted. c Heavy case years averted. Heavy burden was defined as an epg≥ 400. The total effectiveness was the total shaded area
across the full-time horizon. The metrics are described in more detail in [76]
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Fig. 4 The impact of annual school-based treatment on the mean worm burden in different age groups. The solid bars represent the pre-control
burden and the hashed bars, the burden after 5 years of treatment. The scenarios for the relative pre-control burden in adults are shown in Fig. 2
(note they have the same age-weighted overall mean worm burden). The results assume a treatment coverage of 75% and 5% systematic
non-compliance. The results pertaining to the lower transmission setting are shown in Additional file 1: Figure S1. Abbreviation: Pre-SAC: 2–4
year-olds, SAC: 5–14 year-olds and adults: ≥ 15 year-olds
Fig. 5 The impact of annual school-based treatment and community-wide mass treatment on the prevalence of heavy infections in SAC and
adults. The solid lines represent the prevalence of heavy infection in SAC and the dashed the prevalence of heavy infection in adults. The different
scenarios for the relative pre-control burden in adults are indicated with different coloured lines (see Fig. 2). Heavy infection was defined
as having a burden above the WHO threshold (≥400 epg) [2]. The results assume a treatment coverage of 75% and 5% systematic non-compliance.
Abbreviation: SAC: 5–14 year-olds and adults: ≥ 15 year-olds
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scenarios with a higher pre-control burden in adults have
a greater relative benefit of using community-wide mass
treatment (Table 2). The estimated relative increase in
effectiveness was highest when using prevalent case
years averted as the effectiveness metric, and was con-
siderably lower in many settings when using the metrics
based on infection intensity (either worm years or
heavy infection case years averted). For example, when
assuming a relatively low pre-control burden in adults,
the increase in the number of worm-years averted when
using community-wide mass treatment was only 15–
17%, in contrast to an increase of 70–83% for the num-
ber prevalent case years averted.
The incremental increase in effectiveness in terms of
worm years and heavy infection case years averted was
larger in high transmission settings (Table 2). However,
the incremental increase in the number of prevalent
case years averted was higher in lower transmission
settings (Table 2).
In high transmission settings, we found that using
community-wide treatment was not only more effective
for reducing the overall burden of heavy infections but
also more effective for controlling the prevalence of
heavy infections specifically in children (Fig. 5).
Sensitivity analysis
The key results were found to be robust with respect to
the sensitivity analyses performed - though the precise
estimated benefit of community-wide mass treatment
showed some variation (Additional file 1: Tables S3-S6).
Of particular note was, the projected benefit of switch-
ing to community-wide mass treatment decreased when
assuming a lower coverage of adults (Additional file 1:
Table S3). In contrast, when assuming a scenario where
community-wide treatment would decrease the level of
systematic non-compliance in SAC, its benefit increased
(Additional file 1: Table S6).
Impact on transmission and projected rounds to elimination
The impact of school-based treatment on the overall
level of transmission varied in the different scenarios.
However, even when assuming a relatively low pre-
control burden in adults and a high coverage of SAC,
the reservoir in the untreated adults and SAC still had
important implications for the level of ongoing transmis-
sion (Fig. 6). In other words, even though these lower in-
tensity infections may not always be sufficient to justify
community-wide mass treatment when focussing on
morbidity control, they can become significant when try-
ing to break transmission (Fig. 6). These results are mir-
rored when looking at the number of rounds required to
break transmission (Fig. 7) and suggest that when the
goal is eliminating transmission, community-wide mass
treatment is the best strategy in most settings. However,
the results indicate that in high transmission settings it
may not be feasible to break transmission with annual
preventive chemotherapy alone (Fig. 7 and Additional
file 1: Figure S2) [4, 6].
Sensitivity analysis
When assuming a higher rate of systematic non-
compliance (such as 20%), achieving elimination was
projected to be less feasible, requiring more treatment
rounds and higher coverage rates (Additional file 1:
Figure S2). If a lower mean life expectancy of the adult
worms was assumed during the model fitting (4 years
instead of 5.71), the projected number of rounds to
elimination was generally slightly higher, though the
overall findings remained consistent (Additional file 1:
Figure S3).
Table 2 Projected incremental increase in effectiveness when using annual community-wide versus school-based treatment
Effectiveness metric Relative pre-control
worm burden in adults
Incremental increase in effectiveness (relative increase in effectiveness)
Higher transmission setting Lower transmission setting
Average number of worm-years
averted per person
Low 306 (17%) 107 (15%)
Medium 481 (30%) 155 (23%)
High 948 (80%) 314 (59%)
Prevalent case years averted
(per 100 individuals)
Low 146 (83%) 176 (70%)
Medium 168 (124%) 223 (99%)
High 237 (303%) 305 (258%)
Heavy case years averted
(per 100 individuals)
Low 27.1 (23%) 8.1 (12%)
Medium 44.5 (43%) 11.4 (18%)
High 85.5 (118%) 26.7 (52%)
The scenarios for the relative pre-control burden in adults are shown in Fig. 2 (note they have the same age-weighted overall mean worm burden). The results
assume a treatment coverage of 75% and 5% systematic non-compliance. The analysis was conducted with a five-year implementation period and a 15-year time
horizon (i.e. looking at the effect of five years of treatment for 15 years)
Turner et al. Parasites & Vectors  (2017) 10:213 Page 6 of 15
The results presented in Fig. 7 and Additional file 1:
Figures S2-S3 assumed that the rate of systematic non-
compliance was the same, for both school-based and
community-based treatment programmes. However, it is
possible that expanding treatment from schools into
the community to reach adults could also increase the
number of SAC regularly receiving treatment (as non-
enrolled SAC could also be reached more effectively).
In such circumstances, the benefit of expanding treat-
ment into the community for eliminating transmission
would be greater (Fig. 8).
Discussion
The benefit of community-wide mass treatment
Community-wide mass treatment was found to be more
effective for controlling the transmission of schistosome
Fig. 7 The projected number of years of annual treatment required to achieve elimination of Schistosoma mansoni. The scenarios for the relative
pre-control burden in adults are shown in Fig. 2 (note they have the same age-weighted overall mean worm burden). The results assume 5%
systematic non-compliance (and therefore the coverage cannot be higher than 95%). Abbreviation: NA, not achievable within 15 years of
annual treatment
Fig. 6 Comparison of the impact of annual school-based treatment and community-wide mass treatment on the overall mean worm burden.
The scenarios for the relative pre-control burden in adults are shown in Fig. 2 (note they have the same age-weighted overall mean worm burden).
The results assume a treatment coverage of 75% and 5% systematic non-compliance
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parasites, than using a school-based programme only tar-
geting SAC. However, in the context of morbidity control,
the potential benefit of switching to community-wide mass
treatment was variable across the different scenarios
explored. The benefit was found to be highly dependent on
the transmission intensity, the level of school enrolment/
compliance to treatment, and the relative pre-control
worm burden in adults. This has important implications
regarding the generalisability of any cost-effectiveness
analysis of schistosomiasis interventions. The results
indicate that in some settings the indirect benefits of a
school-based programme on the untreated adults may
mean that community-wide mass treatment is unlikely
to be more cost-effective in terms of preventing
morbidity. This implies that, in settings where the
goal is morbidity control, the best strategy may be to
scale-up the geographical coverage of the school-based
programmes (which is currently low in many settings
[30]) and prioritise community-wide mass treatment
in settings where the burden in adults and transmis-
sion intensity are known to be high, or where school
enrolment is poor.
It is important to note that though regular annual
community-wide mass treatment may not always be ad-
visable for morbidity control, this does not mean that
high-risk adults should not be targeted when possible,
particularly pregnant women [31, 32] and those in high-
risk occupations, such as fishermen. Where resources
are too limited to permit expansion to community-wide
mass treatment, a potential solution could be to further
encourage treatment of the parents of SAC within the
school-based programmes or through other existing
platforms such as Child Health Days.
Longer term, there is a shifting emphasis towards
transmission elimination by WHO. With this aim, our
analyses clearly show a benefit of community-wide mass
treatment in most situations and it indicates that it
would be required in order to succeed within a feas-
ible time frame in most settings - with the exception
of low transmission settings where there is little infec-
tion in adults. However, the projections also indicate
that in high transmission settings it may not be pos-
sible to break transmission using annual rounds of
preventive chemotherapy alone, and using other strategies
such as increasing the treatment frequency, health
education, WASH, and snail control, should also be
considered [4, 6, 12]. When evaluating the cost-
effectiveness of incorporating these alternative strategies,
it will be important to consider the benefit of pre-
venting hotspots reseeding the infection to other
areas and communities.
School-enrolment
School enrolment rates vary considerably both within
and between sub-Saharan African countries. For ex-
ample, UNICEF reports a number of settings where the
net attendance rates are lower than 70% (with some as
low as 21%), as well as a large disparity between urban
and rural areas [33]. It is also important to consider that
children may enrol in primary school but, due to unpaid
school fees or seasonal work have to drop out [33]. For
example, in Malawi 93% of children will enrol in primary
school; however, only 48% will complete it [33]. Conse-
quently, in the most marginalised and rural communities
within a country very few children may be completing
primary school.
Fig. 8 Potential impact of annual community-wide mass treatment decreasing the rate of systemic non-compliance in school-aged children. The
results pertain to the scenario with a relatively low pre-control worm burden in adults (Fig. 2). When assuming a systematic non-compliance rate
of 20%, it is not possible to get a 95% coverage of SAC (indicated by a dash in the figure). Abbreviation: NA, not achievable within 15 years of
annual treatment
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Using a community-wide mass treatment strategy
would likely improve the coverage and compliance of
non-enrolled SAC - who can be missed when only using
a school-based strategy. Analyses indicate that this can
have notable implications for the benefit of switching to
community-wide mass treatment for both morbidity
control and eliminating transmission (Fig. 8 and Additional
file 1: Table S6). This further highlights that areas with poor
school-enrolment/coverage (or with high school dropout
rates) should be prioritised for any shift to community-
wide treatment.
Variation in the observed and predicted impact of
community-wide mass treatment
A fundamental reason why studies [15–18] find con-
trasting results regarding the benefit of community-wide
mass treatment is the variation in the relative worm bur-
den harboured by adults across different geographical
settings; the higher the pre-control burden in adults, the
larger the benefit of switching to community-wide treat-
ment (Fig. 1). A second and often overlooked reason is
the way the trial or model is implemented. For example,
the age grouping used for the different treatment categor-
ies, how the data are categorised, and the time horizon for
the analysis, can all influence the estimated strength of the
indirect benefit of school-based treatment on the un-
treated adults. Consequently, these influence the benefit of
switching to community-wide mass treatment.
When evaluating different interventions against schis-
tosomiasis, it is vital to account for the shape of the age-
intensity profile prior to control. This is illustrated in
Fig. 9, which compares the model’s projected impact of
school-based treatment when (a) the model is fitted to
fully age-structured data, which therefore accounts for
the true shape of the age-intensity profile, and (b) the
model is only fitted to the mean burdens of the SAC
and adult age groups, i.e. using the summary statistics
from the same dataset for these two age classes. This
shows that if the shape of the infection profile is not
accounted for, the burden of infection in different age
groups and the impact of different interventions can be
incorrectly quantified (Fig. 9). Specifically, not account-
ing for the infection profile’s shape can lead the model
to underestimate the impact of school-based treatment
(Fig. 9). In the example shown in Fig. 9, the more simple
fitting method would result in the model overestimating
the long-term incremental effectiveness of community-
wide mass treatment between 29 and 42% for the different
metrics investigated (Additional file 1: Table S7). This
highlights the importance of using fully age-structured
models in analyses investigating the impact of targeting
different age groups, particularly for cost-effectiveness
analyses. The difference between the two fitting methods
will vary across different settings and will be dependent on
the shape of the infection profile.
We would also like to highlight that it is important to
understand in which individuals the burden of heavy-
intensity infections remains after school-based treatment.
For example, Fig. 9 shows that for the modelled setting,
the majority of heavy infections remaining are in 20–30
year-olds. If a treatment intervention could be targeted at
this remaining high-risk group, expanding to the whole
community could be unnecessary for morbidity control in
some settings, allowing resources to be redirected to im-
proving coverage and compliance.
Effectiveness metrics and morbidity control
The benefits of switching to community-wide mass treat-
ment for schistosomiasis morbidity control were found to
be very dependent on the choice of the effectiveness metric.
i.e. what method has been used to approximate treatments
impact on morbidity.
Fig. 9 Modelling the indirect benefit of annual school-based treatment on the prevalence of heavy infection. a The model was fitted to fully
age-structured data (and therefore accounts for the true shape of the age-intensity profile) [4]. b The model was only fitted to reproduce the
estimated mean pre-control worm burdens in SAC and adults from the same dataset. The data are from the Iietune village (Kenya) [64] (Fig. 1).
The results assume a treatment coverage of 75% and no systematic non-compliance
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The Disability-Adjusted Life Year (DALY) burden of
schistosomiasis is often calculated by simply applying a
disability weight, representing the disability of an ‘aver-
age’ prevalent case of schistosomiasis, to the prevalence
of infection. However, it is important to note that the
aim of disease burden studies (such as the global burden
of disease (GBD) [34]) is to approximate the disease bur-
den at a given point in time. We believe that for schisto-
somiasis it is misleading to apply this same framework
to estimate the morbidity averted over time due to an
intervention, i.e. calculating the number of DALYs
averted by applying a disability weight to the number of
detectable prevalent-case years averted. This is because
the morbidity associated with schistosomiasis is complex
and often not due merely to the presence or absence of
infection [35–50]. Even the early stages of schistosomiasis-
related morbidity (such as diarrhoea, anaemia, and calorie
undernutrition), have been found to have a relationship (at
least in part) to the individual’s intensity of infection
[46–51]. This is important since when morbidity is re-
lated to the intensity of infection, estimating the impact
of treatment on morbidity based solely on reductions in
infection prevalence may result in a misleading quantifica-
tion, particularly regarding the impact of treating different
age groups. The key reasons for this are as follows:
(i) Considering only reductions in prevalence assumes
that all infections are equally pathogenic and that
reducing the intensity of someone’s infection but not
curing it, has no health benefit. This is particularly
significant for this research question as infection
intensity tends to decrease in older age groups
(Fig. 1). Furthermore, if infections are more
pathogenic in children, estimating reductions in
morbidity based on reductions in prevalence alone
could overestimate the benefit and cost-effectiveness
of switching to community-wide treatment. It
should be noted that a recent systematic review and
meta-analysis concluded that reductions in egg
output are significantly correlated with decreased
schistosomiasis-related morbidity [52].
(ii)Due to the nonlinear relationship between infection
intensity and prevalence, treatment at high-intensity
levels can result in a large reduction in average
infection intensity but have only a small impact on
prevalence (Fig. 10 [29]). Conversely, at lower intensity
levels a small impact on infection intensity will lead to
a dramatic reduction in prevalence (Fig. 10).
The nonlinear relationship between infection intensity
and prevalence (Fig. 10) is why the number of prevalent
case years averted was projected to be higher in the
lower transmission setting by our model. This would
imply that when modelling reductions in morbidity
based on reductions in prevalence, the results could find
that it is more cost-effective to treat in the lower trans-
mission settings. The other investigated metrics found
the opposite relationship and a greater impact in higher
transmission settings.
When assessing studies evaluating the burden of schis-
tosomiasis it is also important to consider that late stage
morbidity may be permanent (or at least not cured by
praziquantel treatment). This means that it is likely that at
least some of the morbidity in adults will not be resolved
by treatment - as it may be a consequence of the infection
burden they had throughout childhood. Previous model-
ling studies have successfully captured trends in morbidity
data using functions which relate morbidity to the accu-
mulated past experience of infection [53–57]. The 2010
GBD study now includes separate calculations for the
more advanced forms of schistosomiasis-related morbid-
ity, such as hepatic inflammation, hematemesis, and asci-
tes [58]. However, it is important to note that it does not
include advanced urogenital diseases, infertility, or the late
effects of growth stunting and cognitive impairment [58].
Burden of light infections
An important area of uncertainty regarding the benefit
of community-wide mass treatment is the potential mor-
bidity associated with active light infections; if their morbid-
ity is high it would increase the benefit of community-wide
mass treatment. These will be more frequently identified in
field epidemiological studies with the new diagnostic tests
(such as the CCA assay [59]) which have a greater sensitiv-
ity than egg counts in stool or urine. It is becoming increas-
ingly recognised that the potentially subtle morbidity that
results from low-intensity infections may be greater than
previously thought and that even low-intensity infections
may limit the productivity and reduce the wellbeing of in-
fected adults [46, 52, 58, 60–62]. The potential burden of
Fig. 10 The relationship between infection intensity and prevalence.
The relationship is further described in [6, 29]
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these light infections has important implications for the
need to shift towards the elimination of transmission [62].
However, although light intensity infections may lead
to morbidity [46, 52, 58, 60, 61], it is likely that they are
more pathogenic in children than adults. Consequently,
we believe that to account for the benefit of preventing
these active light infections accurately, it is necessary to
have a framework which:
(i) Accounts for the differences in the likelihood of
morbidity in children versus adults at different levels
of infection intensity, i.e. how pathogenic different
levels of infection are in different age groups.
(ii)Accounts for which forms of morbidity are
permanent (and not cured by treatment).
Without this, any conclusions regarding the benefit
of expanding treatment on morbidity would be very
dependent on assumptions that are based on limited
empirical evidence. Overestimating the relative bur-
den of light infections could overestimate the benefit
and cost-effectiveness of switching to community-wide
treatment.
It should be stressed that debate continues about
whether there is a recognised infection intensity or infec-
tion duration threshold below which the risk for disease
from Schistosoma infection becomes negligible [60, 61].
The potential morbidity of light infections is also very
important regarding the benefit of a paediatric formulation
of praziquantel [63]. Previous modelling has suggested that
this would be of limited use in bringing about transmission
elimination [4]. However, depending on the pathogenicity
of these light infections in early childhood, a paediatric for-
mulation of praziquantel could still be highly beneficial for
morbidity control.
The most appropriate effectiveness metrics
The current gaps in knowledge in this area mean that it
is difficult to accurately capture the impact of treatment
on the morbidity related to schistosomiasis within trans-
mission models. We believe that caution should be
employed when interpreting modelling results in this
area - which is the reason we did not attempt to esti-
mate DALY averted within this analysis. In our opinion,
worm-years (which acts as a metric of the cumulative
experience of the population, Fig. 3) and the prevalence
of heavy infections are currently the most informative
metrics for evaluating the impact of different interventions
on schistosomiasis-related morbidity within models. How-
ever, as the evidence in this area evolves and more data
becomes available, the choice of effectiveness metric
should be reassessed/modified, with the concomitant de-
velopment of frameworks that can accurately estimate the
number of DALYs averted.
Limitations in the model projections
The model predictions reported in this paper were para-
meterised for S. mansoni. However, given the similar
estimates of the life expectancies for other Schistosoma
species [22, 64] the overall conclusions should be ap-
plicable to other species where humans are the domin-
ant host in maintaining transmission.
It should be stressed that the field of schistosome epi-
demiology suffers greatly from limited information on
key parameters such as detailed age-intensity profiles,
and the relationship between egg output and worm bur-
den [6]. An important area of uncertainty in the model
projections is whether or not acquired immunity against
the different schistosome species exists and to what ex-
tent it shapes the observed age-intensity profiles [6]. If a
species was to generate a strong acquired immunity re-
sponse, repeated rounds of preventive chemotherapy
would reduce the level of herd immunity in an area of
endemic infection. Over many rounds of treatment, this
would increase reinfection rates (as individuals would
not have the same level of past experience of infection
and would therefore not gain the same level of immun-
ity), which would act to lessen the long-term impact of
preventive chemotherapy [6, 54]. This relationship could
be further complicated if treatment induces acquired
immunity [65]. There is also uncertainty regarding the
biology of the long-term mating behaviour of the adult
worms [66, 67] and therefore the most appropriate
mating function to use within the models [6, 68]. Fur-
thermore, it important to note that the model does not
account for migration or animal reservoirs. In addition, the
model’s structure implicitly assumes that hosts contribute
infectious material to a single reservoir (that is shared
for the entire population) and the degree of parasite ag-
gregation (defined by the negative binomial probability
distribution) is assumed to be fixed.
It should also be noted that the scenarios for the rela-
tive pre-control burden in adults were informed by the
limited age-stratified infection intensity data available and
that there may be settings that fall outside this range - in-
cluding variation of the age at which infection intensity
peaks. This highlights the need for more high quality fully
cross-sectional data regarding schistosomiasis infection
levels in all age classes but especially adults, particularly as
the global goals shift to transmission elimination. These
data are often lacking due to the programmatic and logis-
tical difficulties of performing the current diagnostic tests
in communities.
Currently, the model’s prevalence estimates do not ac-
count for which infections would be detectable with the
available diagnostic tests. When adjusting for this, it is im-
portant to account for the fact that the sensitivity of the
diagnostic tests, will likely decrease as infection intensity
decreases, i.e. the sensitivity of the test is not a constant.
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Programmatic issues and considerations for future
economic evaluations
Currently whether or not adults are targeted within
schistosomiasis control programmes is based on the
prevalence of infection in SAC [2]. However, in a study
in Nigeria [69], the prevalence of infection in SAC, the age
group where most monitoring and evaluation activities
and data collection is focused, was not a successful indica-
tor of the burden of infection in adults. The pre-control
burden in adults will likely be driven by a number of local
behavioural and cultural factors, and will, therefore, vary
across different countries (and even different regions
within countries). This makes it difficult to make a univer-
sal SAC infection prevalence threshold for switching to
community-wide mass treatment. This further highlights
the need for more cost-effective rapid diagnostic tests that
allow adults to be sampled more feasibly in a program-
matic context [70].
In January of 2012 (as part of the London Declaration
on NTDs), Merck KGaA pledged to increase its prazi-
quantel donation from 50 million to 250 million tablets
a year for as long as needed [5, 71]. This donation has
greatly increased the availability of praziquantel, but it is
still less than one-half of the more than 500 million tablets
needed annually to treat everyone (children and adults) at
risk under the current thresholds for treatment [72]. Po-
tential praziquantel shortages need to be considered when
considering the cost of expanding the use of community-
wide treatment.
It should be noted that some school-based treatment
programmes are financed by the Ministries of Education
of endemic countries (and not the Ministries of Health).
This needs to be considered when interpreting the conclu-
sions of any cost and cost-effectiveness analysis of switch-
ing to community-wide mass treatment - as the same
funds may not always be available (which will significantly
change the incremental cost of changing strategy).
A further important programmatic consideration for
treating continuously across entire communities is the
potential risk of drug resistance developing. The current
reservoir of untreated worms in adults may be diluting
any resistant gene pool in children and therefore
expanding treatment could increase the risk of drug
resistance. This issue needs careful monitoring with
more research to define markers to track via molecular
epidemiological studies [73].
One of the most urgent research needs for both schisto-
somiasis and the soil-transmitted helminths is for detailed
costing studies that investigate how the delivery costs of
preventive chemotherapy may change when switching to a
community from a school-based treatment programme
(as well as the potential costs of integrating treatment
of adults into other control programmes) [74–76]. In
addition, many NTD control programmes are now
integrated, and in some settings they may have already
established community-delivery platforms which could
also be used for schistosomiasis treatment, allowing the
treatment of adults at a smaller incremental cost. The
potential integration of NTD programmes can have im-
portant implications regarding the cost-effectiveness of
different strategies [8, 9].
Switching to a community-wide mass treatment strat-
egy could be cost-saving in many settings in the long
term - due to its capacity to break transmission with
fewer treatment rounds (Fig. 7). However, when investi-
gating these potential cost-savings it will be important to
consider the risk of human migration resourcing infec-
tion; transmission models can be useful in evaluating the
risk of this and potential management strategies. It will
also be important to consider the implications of poten-
tial hybridization of different Schistosoma species, which
could increase their geographical range if it changes
which snail species are viable intermediate hosts making
elimination more challenging [77–79], as well as the po-
tential role of animal reservoirs [79, 80].
Further studies are needed to assess the coverage and
compliance of different age groups achieved when using
different treatment delivery methods [27]. It will also be
important to investigate the costs (and achieved cover-
age) of targeting high-risk adults and how this compares
to the costs of targeting the whole community. If a suffi-
cient coverage of high-risk adults could be achieved, it
could be a more cost-effective alternative to switching to
community-wide mass treatment.
Within this paper, we did not evaluate the benefit of
the treating Pre-SAC and this should be explored in
future work.
It is also important to recognise that urogenital schisto-
somiasis may have a role in human immunodeficiency virus
(HIV) and human papillomavirus (HPV) infections [81–83]
and could potentially make co-infected individuals more
infectious [82, 84]. This suggests that community-wide
treatment for schistosomiasis could have benefits on other
diseases - which are not captured in this study. The poten-
tial impact of schistosomiasis on other diseases should be
researched further and considered in policy decisions.
Conclusions
Community-wide mass treatment was found to be more
effective for controlling schistosome infection than using
a school-based programme only targeting SAC. However,
its relative benefit was highly variable across the different
scenarios explored. For example, the incremental impact of
community-wide mass treatment relative to school-based
treatment was very dependent on the local epidemiological
setting and the method used to approximate the impact of
treatment on morbidity, i.e. was the effectiveness metric
based on reductions in infection prevalence or reductions
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in infection intensity. This has important implications
regarding the generalisability of cost-effectiveness analyses
of schistosomiasis interventions. Due to our limited un-
derstanding of the causal link between schistosomiasis
morbidity and infection, we believe that caution should be
employed when interpreting modelling results regarding
the amount of schistosomiasis morbidity averted by differ-
ent treatment strategies. In particular, our results highlight
that basing the effectiveness/disease metric solely on re-
duced infection prevalence may produce misleading con-
clusions and that this area needs further research. It is
important to highlight that although switching to regular
annual community-wide mass treatment may not always
be advisable, this does not mean that high-risk adults
should not be targeted when possible. For areas where the
goal is to eliminate transmission, the projected benefit of
community-wide mass treatment was more consistent.
Ultimately, whether community-wide mass treatment is
appropriate will depend on the epidemiological and
programmatic setting, i.e. the relative pre-control burden
in adults, school enrolment and transmission intensity,
and whether the goal is morbidity control or eliminating
transmission. This work highlights the importance of not
over-generalising conclusions and policy in this area, but
of basing decisions on high-quality epidemiological data
and quantitative analyses of the impact of interventions in
a range of settings.
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